Computational modeling manifesto(Addyman & French, ToPICS, 2012)1.Let EVERYONE run your simulations(easily)2.Let motivated users adjust parameters/run their own simulations3.Let other modelers use your code4. Write good documentation5. Clear mapping between model and empirical data6. Show internal structure7. Allow import/export to Excel, etc
Parkinson’s Disease• Neurodegenerative condition due to death ofdopamine producing cells in brain.• Motor / movement related symptoms• Later cognitive problems & effects ofmedication• Levodopa (L-DOPA), a dopamine precursor• Affects 1.1 million people in Europe (127,000 inUK)• Cost of care/medication €10.7billion per year (€7,000 per patient per year.)• Symptoms can be highly sensitive to dose andtiming of medication.
SBRI• Phase 1 funding £75,000 from NHS HealthEnterprise East• 6 month development and pilot testing• Lambert 4 commercial agreement betweenBirkbeck & uMotif• Research costs• 5% royalty on sales• Cure Parkinson’s Trust – access to people withParkinson’s
Randomized Control Trial• 40 participants in two groups• PARTIAL - Self report only• FULL - Self report + objective measures• Use tracker for 2 months• Questionnaires before & after:• Medicine compliance• Parkinson’s symptoms• Oxford Happiness Index• Multidimensional Personality assessment• Quality of Life Scale for people withchronic illness
Trial: 41 recruited,26 used application,16 completed de-briefing70%Av. daily use during 2month trial period“Excellent in conceptionand ease of use”“I find it very attractive &extremely easy to use”Patient Feedback:
Pre & post test questionnaires (n=16)74767880828486889092START ENDPDQ-39ScorePDQ-39 ScoresFULL APPLIMITEDAPP024681012141618START ENDNMSScoreNon-Motor SymptomsFULL APPLIMITEDAPP024681012141618START ENDQOLSScoreQuality of Life Score (QOLS)FULL APPLIMITEDAPP11.522.533.5START ENDMedicinesScoreMoritsky Medicines compliance(Higher is worse)FULL APPLIMITED APP
In – App data - Parkinson’s symptoms11.522.533.544.55START ENDAverageSelfRatingSuppleness scoresFULL APPLIMITEDAPP11.522.533.544.55START ENDAverageSelfRatingTremor scoresFULL APPLIMITEDAPP11.522.533.544.55START ENDAverageSelfRatingDyskinesia scoresFULL APPLIMITEDAPP11.522.533.544.55START ENDAverageSelfRatingBradykinesia scoresFULL APPLIMITEDAPP
In – App data - Mood, Energy & Sleep11.522.533.544.55START ENDAverageSelfRatingMood scoresFULL APPLIMITEDAPP11.522.533.544.55START ENDAverageSelfRatingEnergy scoresFULL APPLIMITEDAPP**† p<.1, ** p<.0111.522.533.544.55START ENDAverageSelfRatingSleep scoresFULL APPLIMITEDAPP†
In – App data - Health Behaviours**** p<.05, *** p<.00511.522.533.544.55START ENDAverageSelfRatingWater scoresFULL APPLIMITEDAPP11.522.533.544.55START ENDAverageSelfRatingExercise scoresFULL APPLIMITEDAPP*11.522.533.544.55START ENDAverageSelfRatingMedication scoresFULL APPLIMITEDAPP
Phase 2 - FUNDED300 patient multi-centre test lasting 6 monthsSuvankar Pal,Rowling Centre and ForthValleyMoAlbazzaz, Barnsley HospitalBen Chico,RotherhamRayChaudhuri, KingsCollegeJulian Fearnley,Barts and The RoyalLondonBeverly Castleton,St Peter’sHospital, SurreyAndrewFowlie, NHSGrampianMax Little,Aston University
• 57 new recreationaldrugs in EU in 2012(EMCDDA)• Most casual drug usersare poly drug users• Self experimentationrequires better data• Big data = better datahttp://www.flickr.com/photos/genista/249525571/The next step.. other drugs?